Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Day E, et al. Among authors: hellard m. Liver Int. 2019 Jan;39(1):20-30. doi: 10.1111/liv.13949. Epub 2018 Sep 22. Liver Int. 2019. PMID: 30157316 Free PMC article. Review.
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM; Australian Trial In Acute Hepatitis C Study Group. Dore GJ, et al. Among authors: hellard m. Gastroenterology. 2010 Jan;138(1):123-35.e1-2. doi: 10.1053/j.gastro.2009.09.019. Epub 2009 Sep 24. Gastroenterology. 2010. PMID: 19782085 Free PMC article.
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.
Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, Hellard M; ATAHC Study Group. Grebely J, et al. Among authors: hellard m. Drug Alcohol Depend. 2010 Mar 1;107(2-3):244-9. doi: 10.1016/j.drugalcdep.2009.09.015. Drug Alcohol Depend. 2010. PMID: 19926405 Free PMC article. Clinical Trial.
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.
Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, Marks P, van Beek I, Rawlinson W, Kaldor JM, Lloyd A, Dore GJ, White PA; ATAHC Study Group. Matthews GV, et al. Among authors: hellard m. Clin Infect Dis. 2011 Mar 15;52(6):803-11. doi: 10.1093/cid/ciq200. Epub 2011 Jan 31. Clin Infect Dis. 2011. PMID: 21282185 Free PMC article. Clinical Trial.
Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.
Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M, Dore GJ, Haber PS; ATAHC Study Group. Alavi M, et al. Among authors: hellard m. J Gastroenterol Hepatol. 2012 May;27(5):957-65. doi: 10.1111/j.1440-1746.2011.07035.x. J Gastroenterol Hepatol. 2012. PMID: 22142332 Free PMC article. Clinical Trial.
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.
Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Vickerman P, et al. Among authors: hellard m. J Infect Dis. 2012 May 1;205(9):1342-50. doi: 10.1093/infdis/jis213. Epub 2012 Mar 29. J Infect Dis. 2012. PMID: 22457292 Free PMC article.
618 results